Literature DB >> 10486934

Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses.

A Katinger1, W Lubitz, M P Szostak, M Stadler, R Klein, A Indra, V Huter, A Hensel.   

Abstract

Aerosol immunization is a safe way to induce complete protection against pleuropneumonia in pigs caused by the lung pathogenic bacterium Actinobacillus pleuropneumoniae. In order to determine the local immune responses of vaccinees in concomitant with protection, lung lining fluid before and 3 weeks after immunization from pigs immunized three times with aerosols of either genetically inactivated ghosts which represent whole cell envelope preparations, or irradiated bacteria were examined following an homologous aerosol challenge. Specific antibody isotypes in the bronchoalveolar lavage were assayed by whole cell ELISAs. Total and relative numbers of cells including lymphocyte subsets were determined. In both vaccinated groups a net influx of plasma cells and lymphocytes, as well as a significant increase of specific IgG occurred. Concurrently, the CD4+/CD8+ ratio was found to increase after aerosol immunization. The lymphocyte subsets of IgG+ and IgA+ cells were found significantly higher in the group immunized with irradiated bacteria when compared to pigs immunized with bacterial ghosts. The latter group showed a significant increase of IgA, IgM, and a net influx of lymphoid blasts and granulocytes in the bronchoalveolar lining fluid. Although differences between the local immune responses of both immunized groups occurred, a significant increase of specific IgG and a net influx of plasma cells and lymphocytes were found to be associated with complete protection against a homologous aerosol challenge infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486934     DOI: 10.1016/s0168-1656(99)00143-1

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  10 in total

1.  Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.

Authors:  Walaiporn Tonpitak; Nina Baltes; Isabel Hennig-Pauka; Gerald F Gerlach
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Generation of Vibrio anguillarum ghost by coexpression of PhiX 174 lysis E gene and staphylococcal nuclease A gene.

Authors:  Se Ryun Kwon; Yue Jai Kang; Dong Jin Lee; Eun Hye Lee; Yoon Kwon Nam; Sung Koo Kim; Ki Hong Kim
Journal:  Mol Biotechnol       Date:  2009-02-04       Impact factor: 2.695

3.  Immunoproteomic analysis of bacterial proteins of Actinobacillus pleuropneumoniae serotype 1.

Authors:  Wei Zhang; Jing Shao; Guangjin Liu; Fang Tang; Yan Lu; Zhipeng Zhai; Yang Wang; Zongfu Wu; Huochun Yao; Chengping Lu
Journal:  Proteome Sci       Date:  2011-06-26       Impact factor: 2.480

4.  Immunoprotective Efficacy of Six In vivo-Induced Antigens against Actinobacillus pleuropneumoniae as Potential Vaccine Candidates in Murine Model.

Authors:  Fei Zhang; Sanjie Cao; Zhuang Zhu; Yusheng Yang; Xintian Wen; Yung-Fu Chang; Xiaobo Huang; Rui Wu; Yiping Wen; Qigui Yan; Yong Huang; Xiaoping Ma; Qin Zhao
Journal:  Front Microbiol       Date:  2016-10-21       Impact factor: 5.640

5.  Subcutaneous Immunization of Dogs With Bordetella bronchiseptica Bacterial Ghost Vaccine.

Authors:  Abbas Muhammad; Johannes Kassmannhuber; Mascha Raucher; Alaric A Falcon; David W Wheeler; Alan A Zhang; Petra Lubitz; Werner Lubitz
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

6.  Formulation and delivery of vaccines: Ongoing challenges for animal management.

Authors:  Sameer Sharma; Lyn A Hinds
Journal:  J Pharm Bioallied Sci       Date:  2012-10

Review 7.  Development of thermostable vaccine adjuvants.

Authors:  Yizhi Qi; Christopher B Fox
Journal:  Expert Rev Vaccines       Date:  2021-06-26       Impact factor: 5.683

8.  Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.

Authors:  Aleksandra Inic-Kanada; Marijana Stojanovic; Simone Schlacher; Elisabeth Stein; Sandra Belij-Rammerstorfer; Emilija Marinkovic; Ivana Lukic; Jacqueline Montanaro; Nadine Schuerer; Nora Bintner; Vesna Kovacevic-Jovanovic; Ognjen Krnjaja; Ulrike Beate Mayr; Werner Lubitz; Talin Barisani-Asenbauer
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

9.  Development of a dual-expression vector facilitated with selection-free PCR recombination cloning strategy.

Authors:  Liting Cao; Yancheng Zhou; Lin Huang; Shiqi Dong; Yue Ma
Journal:  AMB Express       Date:  2017-05-16       Impact factor: 3.298

10.  Harnessing the Immunomodulatory Properties of Bacterial Ghosts to Boost the Anti-mycobacterial Protective Immunity.

Authors:  Jieling Lim; Vanessa Hui Qi Koh; Sharol Su Lei Cho; Balamurugan Periaswamy; Dawn Poh Sum Choi; Maurizio Vacca; Paola Florez De Sessions; Pavol Kudela; Werner Lubitz; Giorgia Pastorin; Sylvie Alonso
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.